Galena Biopharma Announces NeuVax (E75) Improves Disease-Free Survival at 60-Month Median Follow-Up
Lead Drug Candidate – Neuvax Breast Cancer- Neuvax is a vaccine being developed by Galena Biopharma for patients with HER2 Negative Breast Cancer. Such a potential value for Neuvax is great because if successful it can lead to other successful immunotherapies like prostate cancer, and Ovarian Cancer. A vaccine with Breast Cancer indication alone could still yield to multi-billion dollar potential. This lead drug could help a lot of patients to stop the recurrence of breast cancer.
Technology Use – Neuvax - Neuvax is a technology created by Galena biopharma and deals with the next generation of vaccine immunotherapies to potentially treat cancer. The way that Neuvax is works is by using an E75 peptide that binds onto HLA-A2 and HLA-A3 molecules on the surface cells. Think of it this way, the goal is to “train” the immune system to recognize E75 linked to the HLA molecules. The immune system already recognizes E75, so the combination makes it a bulls eye for the immune system to attack those specific cancerous cells, while leaving the healthy human cancer cells alone. (Thus immunotherapy using the body’s own immune system to kill cancerous cells).